{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T03:45:52Z","timestamp":1777520752298,"version":"3.51.4"},"reference-count":30,"publisher":"SAGE Publications","issue":"10","license":[{"start":{"date-parts":[[1997,12,1]],"date-time":"1997-12-01T00:00:00Z","timestamp":880934400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Can J Psychiatry"],"published-print":{"date-parts":[[1997,12]]},"abstract":"<jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>To review the efficacy and safety of moclobemide in comparison with TCAs(for our purposes, \u201cTCAs\u201d will represent tricyclic and tetracyclic antidepressants, including maprotilin and mianserin) and selective serotonin reuptake inhibitors (SSRIs) in elderly depressed patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>The efficacy data reviewed were obtained from the following sources: 1) results of published studies in the elderly; 2) data on patients aged \u2265 60 years extracted from all available controlled trials in adults (\u2265 18 years) in which moclobemide was compared with TCAs or SSRIs; and 3) the adverse events were extracted for patients aged \u2265 60 years from the safety data base of all available comparative short-term studies with moclobemide versus TCAs, SSRIs, or placebo and of long-term studies with moclobemide.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>The data show that moclobemide is an effective antidepressant in depressed patients aged \u2265 60 years. The response rate to moclobemide was 50% to 55% in this population. Moclobemide was more effective than placebo and was of similar efficacy to the TCAs and the more recently introduced SSRIs. The tolerability of moclobemide was rated as \u201cvery good\u201d or \u201cgood\u201d in almost 90% of these patients, which was better than the tolerability of TCAs and similar to that of SSRIs. Patients without any adverse events were more frequently found in the moclobemide group than in those treated with TCAs (P &lt; 0.01) or SSRIs (P &lt; 0.01). Adverse events of the anticholinergic type were more frequent with TCAs than with moclobemide (P &lt; 0.001), and nausea was found 3 times more frequently with SSRIs than with moclobemide (P &lt; 0.01).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Moclobemide is an effective and well-tolerated antidepressant for the treatment of elderly depressed patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/070674379704201005","type":"journal-article","created":{"date-parts":[[2017,1,5]],"date-time":"2017-01-05T15:51:49Z","timestamp":1483631509000},"page":"1043-1050","source":"Crossref","is-referenced-by-count":16,"title":["Efficacy and Tolerability of Moclobemide in Comparison with Placebo, Tricyclic Antidepressants, and Selective Serotonin Reuptake Inhibitors in Elderly Depressed Patients: A Clinical Overview"],"prefix":"10.1177","volume":"42","author":[{"given":"Roman","family":"Amrein","sequence":"first","affiliation":[{"name":"Senior Clinical Research Physician, F Hoffmann-La Roche Ltd, Therapeutics Research CNS, Basel, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Max","family":"Stabl","sequence":"additional","affiliation":[{"name":"Senior Clinical Research Physician, F Hoffmann-La Roche Ltd, Therapeutics Research CNS, Basel, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephan","family":"Henauer","sequence":"additional","affiliation":[{"name":"Medical Director, Pharma Part AG, Zurich, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eva","family":"Affolter","sequence":"additional","affiliation":[{"name":"Senior Safety Data Manager, F Hoffmann-La Roche Ltd, Therapeutics Research CNS, Basel, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iris","family":"Jonkanski","sequence":"additional","affiliation":[{"name":"Safety Data Manager, F Hoffmann-La Roche Ltd, Therapeutics Research CNS, Basel, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[1997,12,1]]},"reference":[{"key":"bibr1-070674379704201005","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/22.5.838"},{"key":"bibr2-070674379704201005","first-page":"3","volume-title":"2nd International Conference on New Directions in Affective Disorders","author":"Manela M","year":"1995"},{"key":"bibr3-070674379704201005","unstructured":"Salzman C, Shader RI, Pearlman M. In: Shader RI, DiMascio A, editors. Psychotropic drug side effects. Baltimore: Williams & Wilkins; 1970. p 261\u201379."},{"key":"bibr4-070674379704201005","unstructured":"Friedel RO. In: Lipton MA, DiMascio A, Killam KF, editors. Psychopharmacology, a generation of progress. New York: Raven; 1978. p 1499\u2013505."},{"key":"bibr5-070674379704201005","doi-asserted-by":"publisher","DOI":"10.1097\/00002826-198901001-00005"},{"key":"bibr6-070674379704201005","doi-asserted-by":"publisher","DOI":"10.1192\/S0007125000297523"},{"key":"bibr7-070674379704201005","doi-asserted-by":"publisher","DOI":"10.1192\/S0007125000297535"},{"key":"bibr8-070674379704201005","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)80090-X"},{"key":"bibr9-070674379704201005","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0447.1995.tb05920.x"},{"key":"bibr10-070674379704201005","first-page":"19","volume":"5","author":"Guentert WT","year":"1994","journal-title":"Reviews in Contemporary Pharmacotherapy"},{"key":"bibr11-070674379704201005","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.168.2.149"},{"key":"bibr12-070674379704201005","doi-asserted-by":"publisher","DOI":"10.1016\/0165-0327(94)00047-D"},{"key":"bibr13-070674379704201005","doi-asserted-by":"publisher","DOI":"10.1002\/gps.930050309"},{"key":"bibr14-070674379704201005","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0447.1990.tb05335.x"},{"key":"bibr15-070674379704201005","doi-asserted-by":"publisher","DOI":"10.1097\/00002826-199417001-00008"},{"key":"bibr16-070674379704201005","doi-asserted-by":"publisher","DOI":"10.1017\/S0924933800000705"},{"key":"bibr17-070674379704201005","doi-asserted-by":"crossref","first-page":"163S","DOI":"10.1017\/S092493380000506X","volume":"9","author":"Altamura AC","year":"1994","journal-title":"European Psychiatry"},{"key":"bibr18-070674379704201005","doi-asserted-by":"publisher","DOI":"10.1007\/BF02246250"},{"key":"bibr19-070674379704201005","first-page":"216","volume":"41","author":"Gershon SC","year":"1988","journal-title":"J Clin Psychopharmacol"},{"key":"bibr20-070674379704201005","doi-asserted-by":"publisher","DOI":"10.1016\/0006-3223(86)90222-2"},{"key":"bibr21-070674379704201005","first-page":"41S","volume":"51","author":"Katz IR","year":"1990","journal-title":"J Clin Psychiatry"},{"key":"bibr22-070674379704201005","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(94)90362-X"},{"key":"bibr23-070674379704201005","doi-asserted-by":"publisher","DOI":"10.1097\/00019442-199621420-00009"},{"key":"bibr24-070674379704201005","doi-asserted-by":"publisher","DOI":"10.1097\/00004850-199609000-00003"},{"issue":"3","key":"bibr25-070674379704201005","first-page":"163S","volume":"10","author":"Holman SL","year":"1994","journal-title":"Neuropsychopharmacology"},{"key":"bibr26-070674379704201005","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199652030-00013"},{"key":"bibr27-070674379704201005","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0447.1995.tb05921.x"},{"key":"bibr28-070674379704201005","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199243040-00009"},{"key":"bibr29-070674379704201005","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/S0022-3565(25)23665-5","volume":"248","author":"Da Prada M","year":"1989","journal-title":"J Pharmacol Exp Ther"},{"key":"bibr30-070674379704201005","doi-asserted-by":"publisher","DOI":"10.1097\/00002826-199417001-00009"}],"container-title":["The Canadian Journal of Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/070674379704201005","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/070674379704201005","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T16:12:22Z","timestamp":1777392742000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/070674379704201005"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1997,12]]},"references-count":30,"journal-issue":{"issue":"10","published-print":{"date-parts":[[1997,12]]}},"alternative-id":["10.1177\/070674379704201005"],"URL":"https:\/\/doi.org\/10.1177\/070674379704201005","relation":{},"ISSN":["0706-7437","1497-0015"],"issn-type":[{"value":"0706-7437","type":"print"},{"value":"1497-0015","type":"electronic"}],"subject":[],"published":{"date-parts":[[1997,12]]}}}